ArticleACS nano2015
In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles.
Article in ACS nano, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 145 citations in OpenAlex.
- The Application of Radiolabeled Mesoporous Silica Nanoparticles in Molecular Imaging.Molecules (Basel, Switzerland) · 2026Review
- Mesoporous silica nanoparticles in glioblastoma: smart nano-platforms for targeted therapy and precision diagnosis.3 Biotech · 2026Review
- Titanium-45 (Pharmaceuticals (Basel, Switzerland) · 2024Review
- Functional Diversity in Radiolabeled Nanoceramics and Related Biomaterials for the Multimodal Imaging of Tumors.ACS bio & med chem Au · 2023Review
- Approaches to Nanoparticle Labeling: A Review of Fluorescent, Radiological, and Metallic Techniques.Environment & health (Washington, D.C.) · 2023Review
- Nanostructured polyvinylpyrrolidone-curcumin conjugates allowed for kidney-targeted treatment of cisplatin induced acute kidney injury.Bioactive materials · 2023Article
- Nanomaterial-based contrast agents.Nature reviews. Methods primers · 2023Article
- Mesoporous silicas in materials engineering: Nanodevices for bionanotechnologies.Materials today. Bio · 2022Review
- Key Parameters for the Rational Design, Synthesis, and Functionalization of Biocompatible Mesoporous Silica Nanoparticles.Pharmaceutics · 2022Review
- Chelator-Free Copper-64-Incorporated Iron Oxide Nanoparticles for PET/MR Imaging: Improved Radiocopper Stability and Cell Viability.Nanomaterials (Basel, Switzerland) · 2022Article
- CoreNanoscale advances · 2022Article
- The upregulated intestinal folate transporters direct the uptake of ligand-modified nanoparticles for enhanced oral insulin delivery.Acta pharmaceutica Sinica. B · 2022Article
- Synthesis and Preliminary Biological Assessment of Carborane-Loaded Theranostic Nanoparticles to Target Prostate-Specific Membrane Antigen.ACS applied materials & interfaces · 2021Article
- Biosafety of mesoporous silica nanoparticles: a combined experimental and literature study.Journal of materials science. Materials in medicine · 2021Article
- Synthesis of Zr-89-Labeled Folic Acid-Conjugated Silica (SiOMaterials (Basel, Switzerland) · 2021Article
- Development of CD133 Targeting Multi-Drug Polymer Micellar Nanoparticles for Glioblastoma - In Vitro Evaluation in Glioblastoma Stem Cells.Pharmaceutical research · 2021Article
- Inorganic-inorganic nanohybrids for drug delivery, imaging and photo-therapy: recent developments and future scope.Chemical science · 2021Review
- Understanding the mechanisms of silica nanoparticles for nanomedicine.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma.Frontiers in bioengineering and biotechnology · 2021Review
- Silica-Based Nanoframeworks Involved Hepatocellular Carcinoma Theranostic.Frontiers in bioengineering and biotechnology · 2021Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Traditional chelator-based radio-labeled nanoparticles and positron emission tomography (PET) imaging are playing vital roles in the field of nano-oncology. However, their long-term in vivo integrity and potential mismatch of the biodistribution patterns between nanoparticles and radio-isotopes are two major concerns for this approach. Here, we present a chelator-free zirconium-89 ((89)Zr, t1/2 = 78.4 h) labeling of mesoporous silica nanoparticle (MSN) with significantly enhanced in vivo long-term (>20 days) stability. Successful radio-labeling and in vivo stability are demonstrated to be highly dependent on both the concentration and location of deprotonated silanol groups (-Si-O(-)) from two types of silica nanoparticles investigated. This work reports (89)Zr-labeled MSN with a detailed labeling mechanism investigation and long-term stability study. With its attractive radio-stability and the simplicity of chelator-free radio-labeling, (89)Zr-MSN offers a novel, simple, and accurate way for studying the in vivo long-term fate and PET image-guided drug delivery of MSN in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.